Hertility conducted a comprehensive study involving over 30,000 women in the UK and Ireland to assess the state of testosterone testing for women. The findings indicate that average testosterone levels used in assessments are based on outdated data, using cohorts that inadequately represent women's health today. As testosterone levels progressively decline from a woman’s 20s, reliance on broad, one-size-fits-all testing methods leads to misdiagnosis and confusion in healthcare practices. Researchers recommend transitioning to age-specific testing standards to enhance diagnostic precision.
The study highlights the inadequacy of current testosterone level data and testing methods for women, pushing for a necessary reevaluation of testing norms.
Unchanged: Current clinical practices based on outdated testosterone data and one-size-fits-all testing procedures continue to be in use.
The tone of the study is cautious as it reveals significant shortcomings in current testosterone testing for women, calling for urgent reforms in the methodology used.
The study advocates for improved methodologies in hormone testing, potentially advancing women's health diagnostics.
Emphasizing the need for age-specific hormone testing may lead to innovations in health technology and improved patient care.
Hertility is leading the charge for reforming hormone testing standards for women's health.
Involved in the academic aspect of the study.
This study's findings challenge the existing standards for hormone testing in women, indicating that many women may not receive accurate diagnoses based on current practices. Improved reference ranges could lead to better health outcomes and clear clinical guidance.
Women may receive false reassurances or unnecessary investigations due to outdated testing methods.
Outdated health standards may disadvantage women's health diagnostics in the UK.
No significant cybersecurity issues linked to this study.
Focuses on health data rather than broader data governance issues.
If practices do not adapt to findings, Hertility could face scrutiny.
Integrating changes into clinical practice may face challenges.
No immediate infrastructure risks identified.
Limited geopolitical implications of the study.
Changes in clinical guidelines and testing standards could face regulatory challenges.
Not applicable to the context of hormone testing.
No direct impact on workforce dynamics.
Not relevant to the focus of the study.